Go to deals
Healthcare | Logistics

A-Med Medical Supply Division has been acquired by Byram Healthcare Centers, Inc.

December 2012 — A-Med Health Care (A-Med) has sold its Medical Supplies Division to Byram Healthcare Centers, Inc. (Byram), a wholly owned subsidiary of Mediq NV. The acquisition represents an EBITDA multiple of approximately 7.5x, excluding synergies.

Founded in 1982 and headquartered in Huntington Beach, California, A-Med is one of the leading distributors of incontinence and urology supplies in the California market serving Medicare, Medicaid / Medi-Cal and managed care patients.

Byram operates as a US subsidiary of Mediq NV, an international company delivering medical devices, pharmaceuticals and related care services. Mediq delivers via three channels: direct to people's homes (Direct), to professional customers such as hospitals, nursing homes and GPs (Institutional) and via Mediq Pharmacies. Mediq operates in 15 countries and has its head office in Utrecht, the Netherlands. This acquisition will establish Byram as a leading provider of medical supplies in the Californian home care market.

A-Med Health Care is a specialty pharmacy providing advanced medications, infusions, supplies, and services to patients living with complex conditions. The company provides support for patients suffering from conditions such as Cystic Fibrosis, HIV/AIDS, Multiple Sclerosis, organ transplants and paraplegia. A-Med Health Care, founded in 1982 and with approximately 200 employees, services patients all across the country.

Our role in the transaction

Oaklins' team in Los Angeles acted as the exclusive financial advisor to A-Med in connection with this asset sale. The transaction was facilitated by Oaklins' team in the Netherlands who identified and contacted Mediq on behalf of the American team. This transaction once again highlights our ability to close deals worldwide.

Parties

Talk to the deal team

Gary Rabishaw

Managing Director
Los Angeles, United States
Oaklins Intrepid

Eduard Bagdasarian

Managing Partner
Los Angeles, United States
Oaklins Intrepid

Maarten Wolleswinkel

Partner
Amsterdam, Netherlands
Oaklins Netherlands

Jeremiah Mann

Managing Director
Los Angeles, United States
Oaklins Intrepid

Related deals

Life & Mobility has attracted investor Bolster Investment Partners
Private Equity | Healthcare

Life & Mobility has attracted investor Bolster Investment Partners

Life & Mobility, a leading developer and manufacturer of premium mobility and rehabilitation solutions, has welcomed Bolster Investment Partners as a new shareholder. The partnership provides Life & Mobility with a strong long-term partner to support the company’s next phase of growth, with a continued focus on product innovation, strengthening its leading market position and further international expansion. The company’s mission remains to enhance the mobility, independence and quality of life of end users through innovative, sustainable and circular mobility solutions designed for multiple life cycles.  

Learn more
Asana Gruppe has sold selected outpatient service areas to Luzerner Kantonsspital
Healthcare

Asana Gruppe has sold selected outpatient service areas to Luzerner Kantonsspital

Luzerner Kantonsspital (LUKS) has acquired key parts of Asana Spital Menziken AG’s outpatient services from Asana Gruppe AG, including its ambulance service, primary care practice and ambulatory care center. The transaction supports the long-term continuity of local medical care in the Swiss Wynen and Seetal regions and ensures these services remain available close to patients’ homes.

Learn more
Laboratoires Herbolistique has received a majority investment from Yotta Capital Partners and co-investors
Private Equity | Healthcare

Laboratoires Herbolistique has received a majority investment from Yotta Capital Partners and co-investors

Laboratoires Herbolistique has received a majority investment from Yotta Capital Partners alongside co-investors Ouest Croissance, Sodero and CE IDF, with Bpifrance, Océans Participations and the management team reinvesting.

Learn more